治疗复发难治弥漫大B细胞淋巴瘤新药:tafasitamab

A new drug in treatment of relapsed or refractory diffuse large B-cell lymphoma:tafasitamab

CD19在弥漫大B细胞淋巴瘤(DLBCL)等B细胞恶性肿瘤中广泛表达。tafasitamab为一种作用于CD19的单克隆抗体,由Morphosys制药公司生产,于2020年7月获美国食品和药物管理局批准联合来那度胺治疗成人复发难治(R/R)且不适合自体干细胞移植的DLBCL(包括由低级别淋巴瘤转化的DLBCL)。临床研究表明R/R DLBCL患者采用tafasitamab联合来那度胺治疗可取得明显的效果,常见不良事件包括中性粒细胞减少、疲劳、贫血、腹泻、血小板减少、咳嗽等,患者可耐受。

CD19 is widely expressed in B cell malignancies,such as diffuse large B-cell lymphoma(DLBCL).Tafasitamab is a monoclonal antibody that acts on CD19,manufactured by Morphosys pharmaceuticals,Inc.It was approved in combination with lenalidomide in the treatment of adult patients with relapsed or refractory(R/R)DLBCL and who are not eligible for autologous stem cell transplant(including DLBCL arising from low grade lymphoma)by the U.S.Food and Drug Administration in July 2020.Clinical studies have shown that tafasitamab combined with lenalidomide can achieve significant results in patients with R/R DLBCL.The common adverse events include neutropenia,fatigue,anemia,diarrhea,thrombocytopenia,cough,and so on.The patients are well tolerated.